Semaglutide 2.4 mg significantly lowered the risk of MACE and mortality in patients with ASCVD and overweight or obesity but without diabetes, researchers reported.
The risks to women's CV health differ, often significantly, from those faced by men, as demonstrated by 5 abstracts from the American College of Cardiology 2025 annual meeting.
ESC 2024: Findings from the FINEARTS-HF clinical trial provide the first definite evidence that an MRA can be beneficial in patients with HFmrEF/HFpEF.
Finerenone treatment achieved a statistically significant reduction in a composite endpoint of CV death and HF events in a population not limited to CKD in T2D, Bayer announced.